BH3 mimetic and dual PI3K/mTOR inhibitor attenuates gemcitabine resistance in triple-negative breast cancer.

Gizem Selimoglu, Suranur Ayvaz, Zeynep Busra Bolat

Abstract read

In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gizem SelimogluDepartment of Molecular Biology and Genetics, Hamidiye Institute of Health Sciences, University of Health Sciences, Istanbul, 34668, Türkiye.

Suranur AyvazDepartment of Molecular Biology and Genetics, Hamidiye Institute of Health Sciences, University of Health Sciences, Istanbul, 34668, Türkiye.

Zeynep Busra BolatDepartment of Molecular Biology and Genetics, Hamidiye Institute of Health Sciences, University of Health Sciences, Istanbul, 34668, Türkiye. zeynepbusra.bolat@sbu.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-Negative Breast Cancer can develop resistance to gemcitabine and overcoming this resistance is critical for effective treatment. In cancer cells, anti-apoptotic Bcl-2 family proteins are often upregulated, disrupting apoptosis. ABT-737 binds to Bcl-2 and Bcl-xL to promote apoptosis but not Mcl-1 protein. NVP-BEZ235, a PI3K-mTOR dual inhibitor, reduces cell proliferation, increases sensitivity to chemotherapeutic agents and overcomes resistance. This study demonstrates the synergistic effects of ABT-737 and NVP-BEZ235 in overcoming gemcitabine resistance Triple-Negative Breast Cancer (MDA-MB-231

Indexed as

DeoxycytidineDrug Resistance, NeoplasmImidazolesMTOR InhibitorsNitrophenolsPhosphoinositide-3 Kinase InhibitorsQuinolinesSulfonamidesTriple Negative Breast NeoplasmsApoptosisBiphenyl CompoundsCell Line, TumorCell ProliferationDrug SynergismFemaleGemcitabineABT-737Biphenyl CompoundsdactolisibDeoxycytidineGemcitabineImidazolesMTOR InhibitorsMTOR protein, humanNitrophenolsPhosphoinositide-3 Kinase InhibitorsPiperazinesQuinolinesSulfonamidesTOR Serine-Threonine KinasesABT-737Gemcitabine resistanceNVP-BEZ235Triple-negative breast cancer

Identifiers

PMID41264053

DOI10.1007/s12032-025-03143-z

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.